2026 Q1 Portfolio Activity
In 2026 Q1, Deep Track Capital, LP maintained a portfolio of 70 distinct positions. The most significant new addition was ALUMIS INC, now representing 2.44% of the total fund value. They heavily accumulated shares in CENTESSA PHARMACEUTICALS PLC, increasing the position by 57.9%. Conversely, Deep Track Capital, LP completely exited their position in DYNAVAX TECHNOLOGIES CORP.
Position History
hover any row below to update
Loading…
Total Positions
70
Quarter
2026 Q1
Top Holding
XBI (20.9%)
Top 10 Concentration
53.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 70
Deep Track Capital, LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 20.86% | 21.74% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
10,000,000 | $1,277,300,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GH
GUARDANT HEALTH...
|
Healthcare | 5.04% | 5.10% |
#2
1
Prev: #3
|
5.5 | 538,241 | 19.2% |
P
S
|
3,338,241 | $308,353,321 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 4.68% | 5.22% |
#3
1
Prev: #2
|
3.9 | no change | no change |
P
S
|
11,526,971 | $286,329,960 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 4.12% | 4.39% |
#4
1
Prev: #5
|
4.1 | 595,966 | 19.8% |
P
S
|
3,600,000 | $252,540,000 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 4.08% | 3.29% |
#5
5
Prev: #10
|
4.1 | 300,000 | 7.5% |
P
S
|
4,300,000 | $249,873,000 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 3.37% | 5.10% |
#6
2
Prev: #4
|
1.8 | 168,066 | 4.1% |
P
S
|
4,279,848 | $206,288,674 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 3.04% | 3.74% |
#7
1
Prev: #8
|
1.7 | -50,000 | -4.3% |
P
S
|
1,100,000 | $185,922,000 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 2.98% | 3.47% |
#8
1
Prev: #9
|
1.2 | -3,217,626 | -41.5% |
P
S
|
4,532,374 | $182,337,406 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.72% | 1.75% |
#9
8
Prev: #17
|
4.1 | 11,615,868 | 143.9% |
P
S
|
19,686,282 | $166,742,809 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 2.70% | 2.55% |
#10
2
Prev: #12
|
3.6 | 1,284,932 | 45.5% |
P
S
|
4,106,067 | $165,187,075 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 2.44% | — |
#11
Prev: #—
|
4.5 | 6,772,595 | — |
NEW
|
6,772,595 | $149,200,268 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 2.39% | 2.40% |
#12
2
Prev: #14
|
3.0 | 250,000 | 14.7% |
P
S
|
1,950,000 | $146,425,500 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NUVL
NUVALENT INC
|
Healthcare | 2.30% | — |
#13
Prev: #—
|
4.4 | 1,376,324 | — |
NEW
|
1,376,324 | $141,004,394 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 2.07% | 1.00% |
#14
12
Prev: #26
|
3.8 | 1,590,323 | 79.5% |
P
S
|
3,590,323 | $126,953,821 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 2.05% | 0.89% |
#15
15
Prev: #30
|
3.8 | 1,158,041 | 57.9% |
P
S
|
3,158,041 | $125,437,389 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 1.95% | 1.08% |
#16
9
Prev: #25
|
3.3 | 1,798,792 | 39.0% |
P
S
|
6,408,863 | $119,461,206 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 1.70% | 3.14% |
#17
6
Prev: #11
|
1.2 | -768,878 | -18.1% |
P
S
|
3,477,562 | $103,805,226 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.63% | 1.17% |
#18
4
Prev: #22
|
1.2 | -127,307 | -5.9% |
P
S
|
2,034,203 | $99,777,657 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 1.61% | 2.38% |
#19
4
Prev: #15
|
1.1 | -691,211 | -9.8% |
P
S
|
6,345,244 | $98,351,282 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GMAB
GENMAB A/S
|
Healthcare | 1.61% | — |
#20
Prev: #—
|
4.1 | 3,663,250 | — |
NEW
|
3,663,250 | $98,284,998 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.48% | 3.78% |
#21
14
Prev: #7
|
0.6 | -1,962,678 | -58.8% |
P
S
|
1,374,320 | $90,581,431 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GRAL
GRAIL INC
|
Healthcare | 1.45% | 1.56% |
#22
4
Prev: #18
|
3.6 | 700,000 | 68.4% |
P
S
|
1,722,797 | $89,034,149 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 1.35% | 1.33% |
#23
3
Prev: #20
|
1.5 | no change | no change |
P
S
|
3,352,804 | $82,680,147 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.34% | 1.83% |
#24
8
Prev: #16
|
1.0 | -492,221 | -15.1% |
P
S
|
2,757,569 | $82,313,435 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 1.32% | 0.78% |
#25
8
Prev: #33
|
3.5 | 1,448,496 | 55.4% |
P
S
|
4,062,500 | $80,803,125 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 1.10% | 0.90% |
#26
3
Prev: #29
|
3.4 | 4,827,173 | 65.8% |
P
S
|
12,161,496 | $67,253,073 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 1.06% | 2.44% |
#27
14
Prev: #13
|
0.4 | -1,150,000 | -50.0% |
P
S
|
1,150,000 | $64,963,500 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.02% | 1.10% |
#28
5
Prev: #23
|
0.9 | 31,303 | 3.9% |
P
S
|
841,445 | $62,485,706 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 0.95% | 1.24% |
#29
8
Prev: #21
|
0.9 | -72,094 | -3.6% |
P
S
|
1,931,884 | $58,246,303 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.94% | 0.39% |
#30
10
Prev: #40
|
2.4 | 295,438 | 12.0% |
P
S
|
2,750,000 | $57,530,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.93% | — |
#31
Prev: #—
|
3.9 | 3,000,000 | — |
NEW
|
3,000,000 | $56,700,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.92% | 0.55% |
#32
5
Prev: #37
|
2.9 | 304,829 | 39.6% |
P
S
|
1,073,877 | $56,614,795 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GERN
GERON CORP
|
Healthcare | 0.77% | 0.77% |
#33
1
Prev: #34
|
0.8 | -790,993 | -2.4% |
P
S
|
31,720,278 | $47,263,214 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ANIP
ANI PHARMACEUTI...
|
Healthcare | 0.75% | 0.67% |
#34
2
Prev: #36
|
2.8 | 122,316 | 25.6% |
P
S
|
600,000 | $46,140,000 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRMD
CORMEDIX INC
|
Healthcare | 0.70% | 1.09% |
#35
11
Prev: #24
|
2.3 | 1,000,000 | 19.0% |
P
S
|
6,274,076 | $42,600,976 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ATAI
ATAIBECKLEY INC
|
Healthcare | 0.69% | 0.34% |
#36
6
Prev: #42
|
3.3 | 7,322,711 | 156.6% |
P
S
|
12,000,000 | $42,480,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.67% | 0.92% |
#37
9
Prev: #28
|
0.3 | -616,759 | -32.4% |
P
S
|
1,283,979 | $40,727,814 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.63% | 0.29% |
#38
6
Prev: #44
|
3.3 | 546,898 | 120.7% |
P
S
|
1,000,000 | $38,490,000 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.60% | — |
#39
Prev: #—
|
3.7 | 2,491,539 | — |
NEW
|
2,491,539 | $36,451,216 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.59% | 0.92% |
#40
13
Prev: #27
|
0.2 | -650,000 | -24.5% |
P
S
|
2,000,000 | $36,260,000 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.59% | 0.83% |
#41
10
Prev: #31
|
2.2 | 78,710 | 7.9% |
P
S
|
1,078,710 | $36,115,211 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 0.57% | — |
#42
Prev: #—
|
3.7 | 9,345,000 | — |
NEW
|
9,345,000 | $35,043,750 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
VERADERMICS INC
|
|
Unknown | 0.52% | — |
#43
Prev: #—
|
3.7 | 500,000 | — |
NEW
|
500,000 | $31,575,000 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
VSTM
VERASTEM INC
|
Healthcare | 0.50% | 0.79% |
#44
12
Prev: #32
|
1.2 | no change | no change |
P
S
|
5,740,850 | $30,426,505 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 0.49% | 0.70% |
#45
10
Prev: #35
|
1.2 | no change | no change |
P
S
|
4,377,572 | $29,811,265 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.45% | 1.40% |
#46
27
Prev: #19
|
0.2 | -1,130,889 | -44.8% |
P
S
|
1,393,944 | $27,265,545 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.43% | 0.36% |
#47
6
Prev: #41
|
2.7 | 1,325,874 | 26.4% |
P
S
|
6,339,535 | $26,182,280 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 0.42% | — |
#48
Prev: #—
|
3.7 | 3,565,062 | — |
NEW
|
3,565,062 | $25,668,446 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 0.40% | 0.55% |
#49
11
Prev: #38
|
1.2 | no change | no change |
P
S
|
1,956,867 | $24,715,230 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 0.39% | — |
#50
Prev: #—
|
3.7 | 285,000 | — |
NEW
|
285,000 | $23,988,450 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-50 of 70 holdings